Proximagen's first-half overshadowed
27 July 2009
Sukaina Virji
Please Login to read the full article.
27 July 2009
Sukaina Virji
sukaina.virji@informa.com
Proximagen Neuroscience's first-half results have been overshadowed by news of its post period £50 million fundraising (scripnews.com, June 5th, 2009).
The funding will be used to acquire CNS drug development programmes and to help build the UK firm into a self-financed company. "Our...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck's Rosenblatt ponders innovation investment's 'grand experiment'
- Panel: Teva's Azilect data close, but no cigar for Parkinson's delay claim
- Valeant prepared to "walk away" from Cephalon if shareholders nix bid
- Loss widens at Proximagen on R&D spend 'that should have been higher'
ANALYSIS
Other Informa Analysis
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
